EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV ‐1 viral load and reservoir size remain stable following SARS ‐ CoV ‐2 mRNA vaccination in people with HIV

Oscar Kieri iD, Bianca B Jütte, Jan Vesterbacka, Soo Aleman iD, Hans-Gustaf Ljunggren, Marcus Buggert iD, J Peter Svensson iD, Anders Sönnerborg, Piotr Nowak iD

HIV Medicine · 2026-07 · 27 (7) · 1120-1131

DOI: 10.1111/hiv.70235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 05.04.2026. Verfasst von Oscar Kieri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Hauptthemen laut MEDLINE: Viral Load, HIV Infections, HIV-1, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stockholm läns landsting, Center for Innovative Medicine, Stiftelsen Läkare mot AIDS Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐dose regimen in people with HIV on antiretroviral therapy (ART).

Methods

We collected blood samples from 37 people with HIV with varying degrees of immune reconstitution before vaccination and after receiving their second and third doses of vaccine. Anti‐SARS‐CoV‐2‐Spike antibodies and Spike‐specific CD4 + T‐cells were analysed as indicators of vaccine‐induced immunogenicity. The Intact Proviral DNA Assay was used to quantify the intact and defective HIV‐1 reservoir.

Results

Vaccination with three doses of SARS‐CoV‐2 mRNA vaccine over the course of 1 year did not result in plasma HIV‐1 RNA rebound nor significantly alter the HIV‐1 reservoir size regardless of immune status. The median intact HIV‐1 reservoir size was 53 (IQR 34–193) copies/million CD4 + T‐cells at baseline and 86 (34–268) and 138 (33–334) 3 months after the second and third dose, respectively ( p > 0.38). We found no correlation between changes in VL or HIV‐1 reservoir size and the anti‐SARS‐CoV‐2‐Spike levels, Spike‐specific CD4 + T‐cells, CD4 + /CD8 + ratio, nadir or CD4 + T‐cell count. However, the intact reservoir size negatively correlated with CD4 + T‐cell count, CD4 + /CD8 + ratio and nadir CD4 + T‐cell count.

Conclusions

Our findings show that three doses of SARS‐CoV‐2 mRNA vaccine did not affect the VL or HIV reservoir size regardless of immune status, supporting their safety in people with HIV. Notably, a higher CD4 + T‐cell count correlated with a reduced intact HIV‐1 reservoir size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral LoadHIV InfectionsHIV-1COVID-19 VaccinesSARS-CoV-2COVID-19HumansMaleFemaleAdultMiddle AgedProspective StudiesRNA, ViralCD4-Positive T-LymphocytesAntibodies, Viral2019-nCoV Vaccine mRNA-1273CD4 Lymphocyte CountVaccination

Stichwörter der Autor:innen

HIV‐1 reservoirSARS‐CoV‐2 mRNA vaccinationimmunological non‐respondersviral load

Substanzen

COVID-19 VaccinesRNA, ViralAntibodies, Viral2019-nCoV Vaccine mRNA-1273

Autor:innen und Institutionen

  • Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Medicine Huddinge, CIM - Clinical Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Translational Pharmacology, Bielefeld University, Medical School OWL, Bielefeld, Germany.
  • Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Oscar Kieri, Soo Aleman, Marcus Buggert, J Peter Svensson, Piotr Nowak

Förderung

  • Stockholm läns landsting
  • Center for Innovative Medicine
  • Stiftelsen Läkare mot AIDS Forskningsfond
  • Karolinska Institutet
  • Vetenskapsrådet

Zitieren

APA

Kieri, O., Jütte, B. B., Vesterbacka, J., Aleman, S., Ljunggren, H. G., Buggert, M., Svensson, J. P., Sönnerborg, A., & Nowak, P. (2026). HIV ‐1 viral load and reservoir size remain stable following SARS ‐ CoV ‐2 mRNA vaccination in people with HIV. HIV Medicine, 27(7), 1120-1131. https://doi.org/10.1111/hiv.70235

Vancouver

Kieri O, Jütte BB, Vesterbacka J, Aleman S, Ljunggren HG, Buggert M, et al. HIV ‐1 viral load and reservoir size remain stable following SARS ‐ CoV ‐2 mRNA vaccination in people with HIV. HIV Medicine. 2026;27(7):1120-1131. doi:10.1111/hiv.70235

BibTeX
@article{Kieri2026,
  author = {Kieri, Oscar and Jütte, Bianca B and Vesterbacka, Jan and Aleman, Soo and Ljunggren, Hans-Gustaf and Buggert, Marcus and Svensson, J Peter and Sönnerborg, Anders and Nowak, Piotr},
  title = {HIV ‐1 viral load and reservoir size remain stable following SARS ‐ CoV ‐2 mRNA vaccination in people with HIV},
  journal = {HIV Medicine},
  year = {2026},
  volume = {27},
  number = {7},
  pages = {1120--1131},
  doi = {10.1111/hiv.70235}
}
Kostenlos starten →